PET scan in clinically suspected paraneoplastic neurological syndromes: A 6-year prospective study in a regional neuroscience unit

Acta Neurologica Scandinavica

Volumn 119, Issue 3, 2009, Pages 186-193

  Hadjivassiliou, M ^a   Alder, S J ^b   Van Beek, E J R ^c   Hanney, M B ^a   Lorenz, E ^a   Rao, D G ^a   Sharrack, B ^a   Tindale, W B ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Immunology; Neuro oncology; Paraneoplastic disorders; PET

Indexed keywords

CANCER ANTIBODY; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BRAIN BIOPSY; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BIOPSY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HEALTH SERVICES ACCESSIBILITY; HOSPITAL UNITS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; NEUROSCIENCES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 59249108684     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01089.x     Document Type: Article

References (12)

1. Luchinetti CF, Kimmel DW, Lennon V. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal a nuclear autoantibodies. Neurology 1998 50 : 652 7.
2. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001 15 : 471 86.
3. Health Technology Board for Scotland. Positron emission tomography imaging in cancer management: staging non-small cell lung cancer. HTA consultation assessment report, 2002.
4. Roman MR, Rossleigh MA, Angelides S et al. Staging and managing lung tumors using F-18 FDG coincidence detection. Clin Nucl Med 2001 26 : 383 8.
5. Weber WA, Neverve J, Sklarek J et al. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system. Eur J Nucl Med 1999 26 : 388 95.
6. Graus F, Delattre JY, Antoine JC et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004 75 : 1135 40.
7. 18F flouro-2-deoxyglucose PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001 124 : 2223 31.
8. Antoine JC, Cinotti L, Tilikete C et al. FDG-PET in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000 48 : 105 8.
9. Linke R, Schroeder M, Helmberger T et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004 63 : 282 6.
10. Younes-Mhenni S, Janier MF, Cinotti L et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004 127 : 2331 8.
11. Koga H, Sasaki M, Kuwabara Y et al. Lesion detectability of a gamma camera based coincidence system with FDG in patients with malignant tumors: a comparison with dedicated positron emission tomography. Ann Nucl Med 2004 18 : 131 6.
12. Rojas I, Graus F, Kleine-Guibert F et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000 55 : 713 5.